NHS organisations awarded £30m to buy research equipment

Thirty-six NHS organisations in England have been awarded a total of £30m from NIHR to pay for new medical equipment and technology.

© Jarmoluk/Pixabay

© Jarmoluk/Pixabay

The funding will support trusts to deliver cutting-edge research to improve the prevention, management and treatment of disease. 

Included in the funding is investment in modular buildings to expand the research capacity and capability in hospitals, many of which are in rural and coastal areas. It will be used for a range of innovative equipment, including imaging devices, ultrasound and MRI scanners, and mobile research vehicles to improve inclusive participation in trials.

While the equipment or technology is primarily for research, it may be used for clinical use during periods of inactivity.

Professor Lucy Chappell, chief executive of the NIHR, said: 'The NIHR is directing this funding so that it reaches the areas and people with the greatest need, giving more communities the chance to take part in life-changing clinical trials.

'This will not only benefit patients directly, but also support the economic growth of the country, helping to position the UK as an attractive place for innovative companies to invest in research.'

BREAKING NEWS: Over 100 neighbourhood health centres to launch by 2030

BREAKING NEWS: Over 100 neighbourhood health centres to launch by 2030

By Lee Peart 26 November 2025

Chancellor Rachel Reeves has announced that 120 of 250 new neighbourhood health centres will be operational by 2030.

Imperial College invests £47.4m in decarbonisation programme

By Lee Peart 25 November 2025

Imperial College Healthcare NHS Trust in north west London is investing £47.4m over the next two years in overhauling its hospitals’ energy systems and reduc...

Personalised 'living drug' for aggressive leukaemia to become available on NHS

By Liz Wells 25 November 2025

An immunotherapy for patients with an aggressive form of leukaemia is to be made available on the NHS after 77% of patients went into remission during trials.


Popular articles by Liz Wells